(NYSE: NVO) Novo Nordisk (Ozempic)'s forecast annual revenue growth rate of 10.82% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 56.37%, and while it is forecast to beat the US market's average forecast revenue growth rate of 9.57%.
Novo Nordisk (Ozempic)'s revenue in 2025 is $46,000,151,745.On average, 1 Wall Street analysts forecast NVO's revenue for 2025 to be $214,109,296,650,000, with the lowest NVO revenue forecast at $214,109,296,650,000, and the highest NVO revenue forecast at $214,109,296,650,000. On average, 3 Wall Street analysts forecast NVO's revenue for 2026 to be $254,593,701,690,000, with the lowest NVO revenue forecast at $246,149,243,650,000, and the highest NVO revenue forecast at $262,812,489,700,000.
In 2027, NVO is forecast to generate $279,525,230,275,000 in revenue, with the lowest revenue forecast at $278,140,254,250,000 and the highest revenue forecast at $280,910,206,300,000.